by webadmin01 | Jul 19, 2023 | Uncategorized
Prestige Biopharma announced today its participation with CancerX, a public-private partnership launched by The White House to accelerate the fight against cancer, as part of the renewed Cancer Moonshot Project. CancerX, a collaborative effort between Moffitt Cancer...
by 김하늘 | Mar 21, 2023 | Uncategorized
Prestige Biopharma has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for PBP1510 (International Non-proprietary name: Ulenistamab), in the treatment of unresectable or metastatic pancreatic adenocarcinoma (PDAC) that has relapsed...
by webadmin01 | Feb 28, 2023 | Uncategorized
SINGAPORE, 28 February 2023 – Prestige Biopharma Limited, a Singapore-based biopharmaceutical company, announced that the company requested Fast Track designation to US Food & Drug Administration (FDA) for its first-in-class anti-PAUF monoclonal antibody...
by webadmin01 | Feb 8, 2023 | Uncategorized
프레스티지 바이오파마의 허셉틴 바이오시밀러 임상 3상 최종 분석 결과가 ‘BMC Cancer’에 게재됐다. 이에 따라 미국과 유럽 판매 허가에 박차를 가하고 있다. 싱가포르 기반의 바이오 제약회사 프레스티지 바이오파마(Prestige Biopharma)는 ‘BMC(BioMed Central)’에 ‘신보조제 환경에서 치료받은 ERBB2 양성 유방암 환자를 대상으로 HD201 vs. ) 암’....
